NephroDI Therapeutics and MSRD partner to develop therapy for NDI
23 Jun 2023
Gene TherapyCell TherapyClinical Study
Preview
Source: Pharmaceutical Technology
NephroDI Therapeutics’ NDI-5001 is being developed to treat X-linked congenital nephrogenic diabetes insipidus, a rare genetic kidney condition. Credit: crystal light / Shutterstock.com.
Preview
Source: Pharmaceutical Technology
NephroDI Therapeutics has signed a deal with the McQuade Center for Strategic Research and Development (MSRD), a member of the global Otsuka group of pharmaceutical companies which is based in Princeton, US, for the development of NDI-5001 to treat nephrogenic diabetes insipidus (NDI).
NephroDI and MSRD will clinically develop the former’s small molecule AMPK activator, NDI-5001, as a potential therapy to treat X-linked congenital NDI, a rare genetic kidney condition.
MSRD will have the option to expand the partnership following the trials, or on reaching specified milestones.
NephroDI Therapeutics CEO Rachael Hagan stated: “X-linked NDI paediatric patients and their caregivers currently navigate a lifetime of intense symptom management. There are minimally effective treatments currently available for NDI that do little to significantly improve the quality of life for patients and their families.
“The NDI, renal and nephrology experts now collaborating across NephroDI, MSRD, and Otsuka are uniquely positioned to embark on the next phase of development for a potential novel NDI treatment.
“This team is driven by the opportunity to bring a first-in-class treatment to these patients and their families.”
The company stated that the later trials are expected to include affected patients.
This will provide a chance for early evidence of target engagement through an increase in urine-concentrating ability.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free Whitepaper
Optimise your cell therapy process: a guide to cell thawing
Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.
This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
By Cytiva Thematic
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.